Status:
UNKNOWN
ERAS Anesthetic Care for Metastatic Spine Cancer Resection
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Metastatic Bone Tumor
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Spinal metastases account for 60% of all malignant bone metastases and represent a medically important treatment goal. For patients with malignant tumors diagnosed at this stage, performing En bloc sp...
Detailed Description
The anesthetic protocol comprises of two major proposed components to enhanced recovery after spine cancer total en bloc resection. First, a multimodal general anesthesia consisting of GABAnergic hypn...
Eligibility Criteria
Inclusion
- Patients undergoing metastatic spine cancer resection surgery
Exclusion
- Expected survival less than 6 months
- Previous surgery or radiotherapy for the spine metastasis
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05427825
Start Date
July 1 2022
End Date
January 1 2024
Last Update
June 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan